11-Keto-beta-boswellic acid

Research use only, not for human use.

11-Keto-beta-boswellic acid, a novel Nrf2 activator, and a selective 5-lipoxygenase (5-LOX) inhibitor.

11-Keto-beta-boswellic acid, a novel Nrf2 activator, and a selective 5-lipoxygenase (5-LOX) inhibitor; it exerts dose dependent cardioprotective effect manifested by dose-dependent reduction in serum lactate dehydrogenaseA total of ten transformed compounds were isolated and purified, and their chemical structures were characterized as 7β-hydroxy-11-keto-β-boswellic acid; 7β, 15α±-dihydroxy-11-keto-β-boswellic acid ; 7β, 16β-dihydroxy-11-keto-β-boswellic acid; 7β, 16α±-dihydroxy-11-keto-β-boswellic acid; 7β, 22β-dihydroxy-11-keto-β-boswellic acid; 7β, 21β-dihydroxy-11-keto-β-boswellic acid; 7β, 20β-dihydroxy-11-keto-β-boswellic acid; 7β, 30-dihydroxy-11-keto-β-boswellic acid; 3α±, 7β-dihydroxy-11-oxours-12-ene-24, 30-dioic acid and 3α±, 7β-dihydroxy-30-(2-hydroxypropanoyloxy)-11-oxours-12-en-24-oic acid by various spectroscopic methods. The biotransformation processes include hydroxylation, oxidation and esterification. Primary structure-activity relationships (SAR) of inhibitory effects on NO production in RAW 264.7 macrophage cells are discussed.

——

Animal Model:Streptozotocin (HY-13753)-induced diabetic rats Dosage:1-10 mg/kg Administration:p.o., for 21 days Result:Reduced blood glucose level.Reduced the serum SGPT, SGOT, ALP, and serum creatinine level.Decreased serum MDA level and increased serum SOD levels.

——

Immunology/Inflammation

Lipoxygenase

5-LOX|NF-κB|leukotriene receptor

——

——

17019-92-0

470.68

C30H46O4

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (106.23 mM)

[H][C@@]12[C@@H](C)[C@H](C)CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@@H](O)[C@](C)(C(O)=O)[C@]3([H])CC[C@@]12C

——

(-20℃)

With Ice Pack

≥ 2 years